Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14453489 | 0.89 | TYMS (0.47) | TYMSDHFR | |
| SCHEMBL166747 | 0.87 | TYMS (0.49) | TYMSDHFR | |
| Hydrochloric Acid SCHEMBL29602465 | 0.85 | TYMS (0.48) | TYMSDHFR | |
| SCHEMBL19929245 | 0.84 | PNP (0.48) | TYMS | |
| SCHEMBL17662614 | 0.82 | PNP (0.46) | TYMS | |
| Hydrochloric Acid SCHEMBL19328559 | 0.81 | PNP (0.46) | TYMS | |
| Hydrochloric Acid SCHEMBL19253833 | 0.81 | PNP (0.46) | TYMS | |
| SCHEMBL17652055 | 0.80 | PNP (0.45) | TYMS | |
| SCHEMBL12820951 | 0.79 | DYRK1A (0.46) | TYMS | |
| SCHEMBL21067593 | 0.79 | TYMS (0.55) | TYMSDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201203-A1 | METHODS OF TREATMENT USING ANTIFOLATES AND PHARMACEUTICAL FORMULATIONS COMPRISING ANTIFOLATES | EMPHASCIENCE, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20230201203-A1 | METHODS OF TREATMENT USING ANTIFOLATES AND PHARMACEUTICAL FORMULATIONS COMPRISING ANTIFOLATES | EMPHASCIENCE, INC. | 2023-06-29 | — | — | US | disclosed |
| US-20190194228-A1 | NEW 1,2,4-TRIAZOLO-[3,4-b]-1,3,4-THIADIAZOLE DERIVATIVES | ENERGONBIO TECHNOLOGIES S.A. (GR) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194228-A1 | NEW 1,2,4-TRIAZOLO-[3,4-b]-1,3,4-THIADIAZOLE DERIVATIVES | CYP4B1, CYP3A4, CYP1B1 | TYMS 69/4885DHFR 362/4885 |
| US-20230201203-A1 | METHODS OF TREATMENT USING ANTIFOLATES AND PHARMACEUTICAL FORMULATIONS COMPRISING ANTIFOLATES | DHFR, MTHFD1, OAT | TYMS 18/4885DHFR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.